Chun-che Lin1, Mei-chin Yin. 1. Dept. of Internal Medicine, Chung Shan Medical University Hospital, No. 110, Sec. 1, Chien Kuo N. Rd, Taichung, 402, Taiwan, ROC.
Abstract
BACKGROUND: This study examined the status of oxidative stress and B vitamins in hepatocellular carcinoma (HCC) patients in different tumor-node-metastasis stages. Patients were divided into two groups as I + II (n = 21) and III + IV (n = 19). METHODS: Plasma levels of lipid oxidation, alpha-tocopherol, beta-carotene, vitamin C, glutathione and the activity of antioxidant enzymes (glutathione peroxidase, superoxide dismutase, catalase, and xanthine oxidase) were determined for evaluating oxidative status. Blood B vitamins (B(1), B(2), B(6), B(12), and folate) and serum ghrelin were analyzed, and the relationship between serum ghrelin and vitamins B(2) (or B(6)) was evaluated. RESULTS: HCC patients at III + IV stage showed significantly lower ghrelin, higher cholesterol, triglyceride, and uric acid than patients at I + II stage and healthy subjects (P < 0.05). Plasma lipid oxidation level in HCC patients was significantly greater than healthy subjects (P < 0.05). The activity of glutathione peroxidase, superoxide dismutase or catalase was significantly decreased, but xanthine oxidase activity was significantly elevated in HCC patients (P < 0.05). Plasma level of glutathione and vitamin C, not alpha-tocopherol and beta-carotene, in HCC patients was significantly lower (P < 0.05). Vitamins B(2) and B(6) levels in red blood cells from these HCC patients were significantly lower (P < 0.05). CONCLUSION: This study provided novel clinical findings regarding the status of oxidative stress and B vitamins in HCC patients. Plasma glutathione level may be a proper biomarker for evaluating oxidative status for HCC patients. Our data indicate that HCC patients might need B vitamins supplementation. The increased serum level of triglyceride and cholesterol might be a consequence of an impaired hepatic fat metabolism, and might be improved by a lower fat administration to these patients.
BACKGROUND: This study examined the status of oxidative stress and B vitamins in hepatocellular carcinoma (HCC) patients in different tumor-node-metastasis stages. Patients were divided into two groups as I + II (n = 21) and III + IV (n = 19). METHODS: Plasma levels of lipid oxidation, alpha-tocopherol, beta-carotene, vitamin C, glutathione and the activity of antioxidant enzymes (glutathione peroxidase, superoxide dismutase, catalase, and xanthine oxidase) were determined for evaluating oxidative status. Blood B vitamins (B(1), B(2), B(6), B(12), and folate) and serum ghrelin were analyzed, and the relationship between serum ghrelin and vitamins B(2) (or B(6)) was evaluated. RESULTS:HCCpatients at III + IV stage showed significantly lower ghrelin, higher cholesterol, triglyceride, and uric acid than patients at I + II stage and healthy subjects (P < 0.05). Plasma lipid oxidation level in HCCpatients was significantly greater than healthy subjects (P < 0.05). The activity of glutathione peroxidase, superoxide dismutase or catalase was significantly decreased, but xanthine oxidase activity was significantly elevated in HCCpatients (P < 0.05). Plasma level of glutathione and vitamin C, not alpha-tocopherol and beta-carotene, in HCCpatients was significantly lower (P < 0.05). Vitamins B(2) and B(6) levels in red blood cells from these HCCpatients were significantly lower (P < 0.05). CONCLUSION: This study provided novel clinical findings regarding the status of oxidative stress and B vitamins in HCCpatients. Plasma glutathione level may be a proper biomarker for evaluating oxidative status for HCCpatients. Our data indicate that HCCpatients might need B vitamins supplementation. The increased serum level of triglyceride and cholesterol might be a consequence of an impaired hepatic fat metabolism, and might be improved by a lower fat administration to these patients.
Authors: Dinesh Talwar; Tara Quasim; Donald C McMillan; John Kinsella; Cathy Williamson; Denis St J O'Reilly Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2003-07-25 Impact factor: 3.205
Authors: Chih-Ching Yeh; Abhishek Goyal; Jing Shen; Hui-Chen Wu; Joshua A Strauss; Qiao Wang; Irina Gurvich; Rachael A Safyan; Gulam A Manji; Mary V Gamble; Abby B Siegel; Regina M Santella Journal: Ann Surg Oncol Date: 2017-06-07 Impact factor: 5.344
Authors: Shen-Chih Chang; Binh Y Goldstein; Lina Mu; Lin Cai; Nai-Chieh Y You; Na He; Bao-Guo Ding; Jin-Kou Zhao; Shun-Zhang Yu; David Heber; Zuo-Feng Zhang; Qing-Yi Lu Journal: Nutr Cancer Date: 2015-01-21 Impact factor: 2.900